MedDataX Logo

Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant

NCT ID: NCT00456482

Last Updated: 2011-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

239 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-05-31

Study Completion Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide intravitreal implants for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye. An additional objective is to compare the safety and efficacy of two doses of fluocinolone acetonide.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-infectious Uveitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fluocinolone Acetonide 0.59mg

Fluocinolone acetonide intravitreal implant 0.59mg

Group Type EXPERIMENTAL

Fluocinolone Acetonide 0.59mg

Intervention Type DRUG

Fluocinolone Acetonide Intravitreal Implant 0.59 mg

Fluocinolone Acetonide 2.1mg

Fluocinolone acetonide intravitreal implant 2.1mg

Group Type EXPERIMENTAL

Fluocinolone Acetonide 2.1mg

Intervention Type DRUG

Fluocinolone Acetonide Intravitreal Implant 2.1 mg

No Intervention

Fellow eye

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluocinolone Acetonide 0.59mg

Fluocinolone Acetonide Intravitreal Implant 0.59 mg

Intervention Type DRUG

Fluocinolone Acetonide 2.1mg

Fluocinolone Acetonide Intravitreal Implant 2.1 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or non-pregnant females at least 6 years of age who had been diagnosed and treated for recurrent,
* Non-infectious uveitis affecting the posterior segment of one or both eyes for at least 1 year prior to the start of the study,
* Had clinically 'quiet' eyes at surgery.

Exclusion Criteria

* Coexistent medical or ocular conditions that would interfere with obtaining or interpreting data for this study.
Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bausch & Lomb Incorporated

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Timothy L Comstock, OD

Role: STUDY_DIRECTOR

Bausch & Lomb Incorporated

References

Explore related publications, articles, or registry entries linked to this study.

Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006 Jun;113(6):1020-7. doi: 10.1016/j.ophtha.2006.02.021. Epub 2006 May 9.

Reference Type BACKGROUND
PMID: 16690128 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

415-004

Identifier Type: -

Identifier Source: org_study_id